Internal Medicine, Endocrinology, Diabetes, & Metabolism · Metairie, LA
NPI
1124268008
Since 2009
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3901 Houma Blvd, Ste 103
Metairie, LA, 70006
Phone (504) 455-1300
Groups this clinician bills Medicare through
Medicare paid, 2024
$86K
1,047 services
Medicare patients, 2024
400
Average age 74
Drug cost, 2024
$3.1M
7,356 prescriptions
Company payments, 2025
$5,350
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Julie M Talavera was code 99214 (office e&m - established), 708 times for 372 patients. In total Julie M Talavera billed 1,047 services in 14 codes, and Medicare paid $86K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 708 | 372 | $96.59 | $68K |
| 95251 Test - Miscellaneous | Office | 197 | 82 | $26.04 | $5,129 |
| 76536 Ultrasound - Nonspecific | Office | 73 | 73 | $78.98 | $5,765 |
| 99204 Office E&M - New | Office | 30 | 30 | $128.07 | $3,842 |
| 99215 Office E&M - Established | Office | 14 | 12 | $138.28 | $1,936 |
By year: 2022 $84K for 1,042 services; 2023 $79K for 1,022 services; 2024 $86K for 1,047 services.
Medicare prescription drug claims, 2024
In 2024, the drug Julie M Talavera prescribed most often to Medicare patients was Levothyroxine Sodium, with 755 prescriptions and refills. In total Julie M Talavera wrote 7,356 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 755 | 2,064 | 192 | $6,428 |
| Ozempic Semaglutide | 429 | 583 | 80 | $563K |
| Tresiba Flextouch U-100 Insulin Degludec | 307 | 518 | 74 | $187K |
| Metformin Hcl Generic | 291 | 801 | 83 | $1,838 |
| Mounjaro Tirzepatide | 259 | 278 | 38 | $286K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 248 | 463 | 79 | $18K |
| Novolog Flexpen Insulin Aspart | 242 | 374 | 63 | $49K |
| Synthroid Levothyroxine Sodium | 222 | 399 | 44 | $12K |
| Metformin Hcl Er Metformin Hcl | 193 | 515 | 54 | $2,160 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 185 | 358 | 51 | $26K |
| Glimepiride Generic | 180 | 520 | 55 | $1,500 |
| Alendronate Sodium Generic | 179 | 474 | 52 | $1,467 |
| Methimazole Generic | 174 | 428 | 46 | $1,449 |
| Jardiance Empagliflozin | 164 | 272 | 46 | $159K |
| Farxiga Dapagliflozin Propanediol | 128 | 190 | 23 | $106K |
Brand drugs: 3,723 claims; generic drugs: 2,924 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Julie M Talavera $5,350 ($5,350 in general payments such as food, travel and fees) from 29 companies. The largest payer was Novo Nordisk Inc with $2,402.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 18 | $2,402 |
| Abbott Laboratories ABT | 16 | $507 |
| Dexcom, Inc. DXCM | 19 | $448 |
| Insulet Corporation PODD | 5 | $239 |
| Xeris Pharmaceuticals, Inc. | 20 | $228 |
| Amgen Inc. AMGN | 11 | $212 |
| Radius Health, Inc. | 9 | $168 |
| Corcept Therapeutics CORT | 9 | $148 |
| Beta Bionics, Inc. BBNX | 10 | $130 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $122 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.